You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾美疫苗(06660.HK):吸附破傷風疫苗正式提交臨牀試驗申請
格隆匯 08-29 20:05

格隆匯8月29日丨艾美疫苗(06660.HK)宣佈,集團吸附破傷風疫苗已於2024年8月向中國藥品監督管理局藥品審評中心(CDE)正式提交了臨牀試驗申請。該疫苗的研發符合公司產品研發戰略佈局,是實現公司研發多聯多價產品的重要一步,將進一步完善公司的產品梯隊,有利於鞏固公司在國內非免疫規劃疫苗(二類疫苗)領域的行業地位,有利於公司疫苗業務的可持續發展。

破傷風是一種極為嚴重的潛在致命性疾病,目前接種破傷風疫苗是預防破傷風最經濟、最有效的措施。此外,集團正在積極推進吸附無細胞百白破-HIB聯合疫苗(以下簡稱「四聯疫苗」)的研發,預計從2024年開始會陸續提交四聯疫苗及其各組分疫苗的臨牀試驗申請。四聯疫苗用於預防百日咳、白喉、破傷風和b型流感嗜血桿菌引起的侵入性感染,具有減少嬰幼兒的接種針次,增強家長和嬰幼兒接種依從性等優勢。多聯疫苗是行業的發展趨勢,根據行業顧問灼識諮詢數據,2022年國內多聯苗市場規模人民幣64.57億元,預計2030年市場規模將達到人民幣95.72億元,對於增強公司的核心競爭力,強化公司的市場地位,為公司持續穩健發展提供強力支持。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account